Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition
CBD September 17, 2020
Robin Lefferts September 17th, 2020 Cannabidiol, or CBD, is thought to be beneficial for a wide variety of ailments, ranging from poor sleep to pain to PTSD and beyond. To this point, however, there haven’t been many clinical trials conducted to thoroughly prove or disprove the benefits of CBD.... Read more
Psychedelics, the Next Frontier in Drug Research
February 28, 2020
Ryan Allway February 28th, 2020 App, Exclusive, News, Top Story A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin... Read more
CFN Media Exclusive Update from FluroTech President and CEO
November 4, 2019
Rachelle Gordon November 4th, 2019 App, Exclusive, News, Top Story In the burgeoning cannabis industry, testing companies are often considered the gatekeepers to success. Between consumer demand and regulatory obligations, marijuana producers are compelled to provide a full analysis of what they’re putting on the market and accurate results... Read more
Ash Stringer August 14th, 2019 App, Exclusive, News, Top Story When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp.... Read more
XPhyto Therapeutics Debuts on CSE Under Ticker XPHY
August 6, 2019
Ryan Allway August 6th, 2019 App, Exclusive, News, Top News After about two years of building relationships with exceptional partners and positioning itself in Canada and Europe, XPhyto Therapeutics (CSE: XPHY) was ready to become a public company. That happened Tuesday morning, with trading beginning on the Canadian Securities... Read more
Ryan Allway June 26th, 2019 App, Exclusive, News, Top Story Many people hear the phrase ‘synthetic’ cannabinoids and immediately think of deadly designer drugs that have swept the recreational market. But synthetic cannabinoids refer to any cannabinoids that are created through chemical or biological processes other than the cultivation... Read more
VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical candidate for... Read more
Ryan Allway March 19th, 2019 Uncategorized CFN Media recently sat down with Gabriella’s Kitchen (CSE: GABY) (OTCBB:GABLF) CEO Margot Micallef to discuss the global implications of Gaby’s innovative products. New beginnings Gabriella’s Kitchen is a cannabis wellness company founded in health and nutrition. Spurred by a dire cancer prognosis, sisters... Read more
Aleafia Becomes First Cannabis Stock to Top TSX Venture 50 Performance Rankings
Uncategorized February 22, 2019
Ryan Allway February 22nd, 2019 Uncategorized The TSX Venture exchange has become a popular place for cannabis companies to list their shares, particularly after Canada legalized recreational cannabis last year, but 2019 was the first year that a cannabis company topped its annual performance rankings. Aleafia Health Inc. (TSX-V:... Read more
International Cannabis to Acquire Over 155 Metric Tonnes of Processed, Extraction-Ready Hemp and 400 Tonnes of Organic Hemp Currently Under Cultivation
February 1, 2019
VANCOUVER, British Columbia, Feb. 01, 2019 (GLOBE NEWSWIRE) — ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC:KNHBF) (“ICC” or “International Cannabis” or the “Company”) is pleased to announce it has entered into an agreement to purchase 155 metric tonnes of processed industrial hemp from Eviana Health Corporation (“Eviana”) (CSE:EHC). International... Read more
